Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1983 Jan;39(1):85–90. doi: 10.1128/iai.39.1.85-90.1983

p105, an Epstein-Barr virus-induced, phosphonoacetic acid-insensitive glycoprotein target of the anti-Epstein-Barr virus immune response.

D Casareale, W Jones, T Sairenji, R E Humphreys
PMCID: PMC347908  PMID: 6295961

Abstract

To describe structures and biological functions of targets for antibody-mediated immune responses to Epstein-Barr virus (EBV)-infected lymphoid cells, we have characterized a membrane-associated protein of 105,000 daltons, p105, which was prominently recognized in immunoprecipitates with some EBV antigen-reactive patients' sera. A rabbit antiserum to immunopurified p105 was developed. [35S]methionine-labeled p105 was specific to EBV-superinfected Raji cells, and its synthesis was not blocked with phosphonoacetic acid, indicating that it is an "early" viral antigen. Phosphonoacetic acid treatment of EBV-superinfected Raji cells was associated with the accumulation, mainly in the cytosol, of an 88,000-dalton protein, p88, which was also recognized with anti-p105 serum, but was not detected in superinfected cells which had not been treated with phosphonoacetic acid. Although anti-p105 serum immunoprecipitated a membrane fraction protein, it did not neutralize P3HR-1 virus and was not considered to be an exposed virion component. We conclude that p105 is an early, EBV-induced, membrane fraction antigen to which EBV-infected patients generate a substantial antibody response.

Full text

PDF
85

Images in this article

86Image
on p.86
87Image
on p.87
87Image
on p.87
88Image
on p.88

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayliss G. J., Nonoyama M. Mechanisms of infection with Epstein-Barr virus. III. The synthesis of proteins in superinfected Raji cells. Virology. 1978 Jun 1;87(1):204–207. doi: 10.1016/0042-6822(78)90173-3. [DOI] [PubMed] [Google Scholar]
  2. Bodemer W. W., Summers W. C., Niederman J. C. Detection of virus-specific antigens in EB-(P3HR1) virus-superinfected Raji cells by immunoprecipitation. Virology. 1980 Jun;103(2):340–349. doi: 10.1016/0042-6822(80)90192-0. [DOI] [PubMed] [Google Scholar]
  3. Bonner W. M., Laskey R. A. A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels. Eur J Biochem. 1974 Jul 1;46(1):83–88. doi: 10.1111/j.1432-1033.1974.tb03599.x. [DOI] [PubMed] [Google Scholar]
  4. Casareale D., Sakamoto K., Aiba M., Katayama I., Purtilo D. T., Humphreys R. E. Sera of patients with hairy cell leukemia immunoprecipitate EBV-related antigens. Leuk Res. 1981;5(2):107–112. doi: 10.1016/0145-2126(81)90068-0. [DOI] [PubMed] [Google Scholar]
  5. Ernberg I., Klein G., Kourilsky F. M., Silvestre D. Differentiation between early and late membrane antigen on human lymphoblastoid cell lines infected with Epstein-Barr virus. I. Immunofluorescence. J Natl Cancer Inst. 1974 Jul;53(1):61–65. doi: 10.1093/jnci/53.1.61. [DOI] [PubMed] [Google Scholar]
  6. Gergely L., Klein G., Ernberg I. Appearance of Epstein-Barr virus-associated antigens in infected Raji cells. Virology. 1971 Jul;45(1):10–21. doi: 10.1016/0042-6822(71)90107-3. [DOI] [PubMed] [Google Scholar]
  7. Henle G., Henle W., Klein G. Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int J Cancer. 1971 Sep 15;8(2):272–282. doi: 10.1002/ijc.2910080212. [DOI] [PubMed] [Google Scholar]
  8. Henle W., Henle G., Zajac B. A., Pearson G., Waubke R., Scriba M. Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science. 1970 Jul 10;169(3941):188–190. doi: 10.1126/science.169.3941.188. [DOI] [PubMed] [Google Scholar]
  9. Hinuma Y., Konn M., Yamaguchi J., Wudarski D. J., Blakeslee J. R., Jr, Grace J. T., Jr Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J Virol. 1967 Oct;1(5):1045–1051. doi: 10.1128/jvi.1.5.1045-1051.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jondal M. Antibody-dependent cellular cytotoxicity (ADCC) against Epstein-Barr virus-determined membrane antigens. I. Reactivity in sera from normal persons and from patients with acute infectious mononucleosis. Clin Exp Immunol. 1976 Jul;25(1):1–5. [PMC free article] [PubMed] [Google Scholar]
  11. Kallin B., Luka J., Klein G. Immunochemical characterization of Epstein-Barr virus-associated early and late antigens in n-butyrate-treated P3HR-1 cells. J Virol. 1979 Dec;32(3):710–716. doi: 10.1128/jvi.32.3.710-716.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kessler S. W. Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A. J Immunol. 1975 Dec;115(6):1617–1624. [PubMed] [Google Scholar]
  13. King J., Laemmli U. K. Polypeptides of the tail fibres of bacteriophage T4. J Mol Biol. 1971 Dec 28;62(3):465–477. doi: 10.1016/0022-2836(71)90148-3. [DOI] [PubMed] [Google Scholar]
  14. Klein G., Pearson G., Henle G., Henle W., Goldstein G., Clifford P. Relation between Epstein-Barr viral and cell membrane immunofluorescence in Burkitt tumor cells. 3. Comparison of blocking of direct membrane immunofluorescence and anti-EBV reactivities of different sera. J Exp Med. 1969 Apr 1;129(4):697–705. doi: 10.1084/jem.129.4.697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Meuller-Lantzsch N., Georg B., Yamamoto N., zur Hausen H. Epstein-Barr virus-induced proteins. II. Analysis of surface polypeptides from EBV-producing and -superinfected cells by immunoprecipitation. Virology. 1980 Apr 30;102(2):401–411. doi: 10.1016/0042-6822(80)90107-5. [DOI] [PubMed] [Google Scholar]
  16. Nyormoi O., Thorley-Lawson D. A., Elkington J., Strominger J. L. Differential effect of phosphonoacetic acid on the expression of Epstein-Barr viral antigens and virus production. Proc Natl Acad Sci U S A. 1976 May;73(5):1745–1748. doi: 10.1073/pnas.73.5.1745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. PULVERTAFT J. V. A STUDY OF MALIGNANT TUMOURS IN NIGERIA BY SHORT-TERM TISSUE CULTURE. J Clin Pathol. 1965 May;18:261–273. doi: 10.1136/jcp.18.3.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Pearson G. R., Johansson B., Klein G. Antibody-dependent cellular cytotoxicity against Epstein-Barr virus-associated antigens in African patients with nasopharyngeal carcinoma. Int J Cancer. 1978 Aug 15;22(2):120–125. doi: 10.1002/ijc.2910220203. [DOI] [PubMed] [Google Scholar]
  19. Pearson G. R., Orr T. W. Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein-Barr virus antigens. J Natl Cancer Inst. 1976 Mar;56(3):485–488. doi: 10.1093/jnci/56.3.485. [DOI] [PubMed] [Google Scholar]
  20. Pearson G. R., Qualtiere L. F., Klein G., Norin T., Bal I. S. Epstein-Barr virus-specific antibody-dependent cellular cytotoxicity in patients with Burkitt's lymphoma. Int J Cancer. 1979 Oct 15;24(4):402–406. doi: 10.1002/ijc.2910240405. [DOI] [PubMed] [Google Scholar]
  21. Qualtiere L. F., Pearson G. R. Epstein-Barr virus-induced membrane antigens: immunochemical characterization of Triton X-100 solubilized viral membrane antigens from EBV-superinfected Raji cells. Int J Cancer. 1979 Jun 15;23(6):808–817. doi: 10.1002/ijc.2910230612. [DOI] [PubMed] [Google Scholar]
  22. Reedman B. M., Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer. 1973 May;11(3):499–520. doi: 10.1002/ijc.2910110302. [DOI] [PubMed] [Google Scholar]
  23. Rogan K. M., Faldetta T. J., Boto W., Aiken J. J., DeMartino J. L., Howe R. C., Spiro R. C., Humphreys R. E. Heterogeneity in the membrane proteins of human lymphoid cell lines as seen in sodium dodecyl sulfate-polyacrylamide electrophoresis slab gels. Cancer Res. 1978 Nov;38(11 Pt 1):3604–3610. [PubMed] [Google Scholar]
  24. Sakamoto K., Aiba M., Katayama I., Sullivan J. L., Humphreys R. E., Purtilo D. T. Antibodies to Epstein-Barr virus-specific antigens in patients with hairy-cell leukemia. Int J Cancer. 1981;27(4):453–458. doi: 10.1002/ijc.2910270406. [DOI] [PubMed] [Google Scholar]
  25. Strnad B. C., Neubauer R. H., Rabin H., Mazur R. A. Correlation between Epstein-Barr virus membrane antigen and three large cell surface glycoproteins. J Virol. 1979 Dec;32(3):885–894. doi: 10.1128/jvi.32.3.885-894.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Summers W. C., Klein G. Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid. J Virol. 1976 Apr;18(1):151–155. doi: 10.1128/jvi.18.1.151-155.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Svedmyr A., Demissie A., Klein G., Clifford P. Antibody patterns in different human sera against intracellular and membrane-antigen complexes associated with Epstein-Barr virus. J Natl Cancer Inst. 1970 Mar;44(3):595–610. [PubMed] [Google Scholar]
  28. Takaki K., Harada M., Sairenji T., Hinuma Y. Identification of target antigen for antibody-dependent cellular cytotoxicity on cells carrying Epstein-Barr virus genome. J Immunol. 1980 Nov;125(5):2112–2117. [PubMed] [Google Scholar]
  29. Weber K., Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem. 1969 Aug 25;244(16):4406–4412. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES